[go: up one dir, main page]

AR099399A1 - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
AR099399A1
AR099399A1 ARP150100410A ARP150100410A AR099399A1 AR 099399 A1 AR099399 A1 AR 099399A1 AR P150100410 A ARP150100410 A AR P150100410A AR P150100410 A ARP150100410 A AR P150100410A AR 099399 A1 AR099399 A1 AR 099399A1
Authority
AR
Argentina
Prior art keywords
salt
compound
carbamimidamidobenzoyl
oxazol
dihydro
Prior art date
Application number
ARP150100410A
Other languages
English (en)
Inventor
Ikeda Zenichi
Sasaki Minoru
Kakegawa Keiko
Kikuchi Fumiaki
Nishikawa Yoichi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR099399A1 publication Critical patent/AR099399A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporciona un compuesto heterocíclico fusionado que tiene una acción inhibidora de la enteropeptidasa, así como el uso del compuesto como medicamento en el tratamiento o la profilaxis de la obesidad, la diabetes mellitus, etc., una sal de él, así como el uso del compuesto como medicamento en el tratamiento o la profilaxis de la obesidad, la diabetes mellitus, etc. Reivindicación 1: Un compuesto representado por la fórmula (1) en donde el anillo A representa un anillo de benceno opcionalmente sustituido de forma adicional; y L¹ y L² representan cada uno de forma independiente un enlace o un grupo C₁₋₃ alquileno lineal opcionalmente sustituido; o una sal de él. Reivindicación 5: Ácido (5R)-3-(3-((4-carbamimidamidobenzoil)oxi)fenil)-5-(carboximetil)-4,5-dihidro-1,2-oxazol-5-carboxílico o una sal de él. Reivindicación 6: Ácido (5S)-3-(3-((4-carbamimidamidobenzoil)oxi)fenil)-5-(carboximetil)-4,5-dihidro-1,2-oxazol-5-carboxílico o una sal de él. Reivindicación 7: Ácido 2,2-(3-(3-((4-carbamimidamidobenzoil)oxi)fenil)-4,5-dihidro-1,2-oxazol-5,5-diil)diacético o una sal de él.
ARP150100410A 2014-02-13 2015-02-12 Compuesto heterocíclico AR099399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014025944 2014-02-13

Publications (1)

Publication Number Publication Date
AR099399A1 true AR099399A1 (es) 2016-07-20

Family

ID=52589730

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100410A AR099399A1 (es) 2014-02-13 2015-02-12 Compuesto heterocíclico

Country Status (22)

Country Link
US (2) US9428470B2 (es)
EP (1) EP3105228B1 (es)
JP (1) JP6458054B2 (es)
KR (1) KR20160113299A (es)
CN (1) CN106170487A (es)
AR (1) AR099399A1 (es)
AU (1) AU2015216439A1 (es)
BR (1) BR112016018548A2 (es)
CA (1) CA2939675A1 (es)
CL (1) CL2016002023A1 (es)
CR (1) CR20160368A (es)
EA (1) EA201691624A1 (es)
EC (1) ECSP16067163A (es)
IL (1) IL247018A0 (es)
MA (1) MA39247B1 (es)
MX (1) MX2016010561A (es)
PE (1) PE20161396A1 (es)
PH (1) PH12016501614A1 (es)
SG (1) SG11201606176YA (es)
TW (1) TW201609677A (es)
UY (1) UY35995A (es)
WO (1) WO2015122188A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57568B1 (sr) 2013-03-13 2018-10-31 Takeda Pharmaceuticals Co Jedinjenje estar guanidinobenzojeve kiseline
WO2015120458A1 (en) 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
US9428470B2 (en) * 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ES2750956T3 (es) 2014-02-13 2020-03-30 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
JP6602778B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
JP6634070B2 (ja) * 2015-03-27 2020-01-22 武田薬品工業株式会社 縮合複素環化合物
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
BR112018002553A8 (pt) 2015-08-12 2023-01-24 Incyte Corp Sais de um inibidor de lsd1
CN111542511A (zh) 2017-11-02 2020-08-14 宇部兴产株式会社 蛋白分解酶的双头型抑制剂
PE20211496A1 (es) 2018-05-09 2021-08-11 Lg Chemical Ltd Nuevo compuesto que presenta actividad inhibidora de enteropeptidasa
TW202024028A (zh) * 2018-08-27 2020-07-01 日商思可海雅藥品股份有限公司 苯甲酸酯化合物
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
SG11202103984WA (en) * 2018-10-23 2021-05-28 Japan Science & Tech Agency PPARd activator
US20220281866A1 (en) 2019-07-19 2022-09-08 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
IL292688A (en) * 2019-11-04 2022-07-01 Faraday Pharmaceuticals Inc Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity
WO2021166899A1 (ja) * 2020-02-17 2021-08-26 宇部興産株式会社 インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
WO1994013631A1 (fr) 1992-12-10 1994-06-23 Teikoku Chemical Industries Co., Ltd. Derive d'acide proprionique
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JPH09124571A (ja) 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
WO1997037969A1 (en) 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターｄ阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja) 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
US7423159B2 (en) 2002-11-01 2008-09-09 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
EP2385032A1 (en) 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Receptor function regulator
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
EP1697339A1 (en) 2003-12-25 2006-09-06 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2006057152A1 (ja) 2004-11-08 2006-06-01 Ono Pharmaceutical Co., Ltd. タンパク質分解酵素阻害化合物からなる糖尿病治療剤
CA2588087A1 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
DE602004015169D1 (de) 2004-11-26 2008-08-28 Nutricia Nv Kleinkindernahrung mit proteasehemmer
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
CN101282725A (zh) 2005-08-10 2008-10-08 武田药品工业株式会社 糖尿病治疗剂
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2635210A1 (en) 2006-01-12 2007-08-02 Merck & Co., Inc. Hydroxyalkylarylamide derivatives
KR101058772B1 (ko) 2006-06-27 2011-08-24 다케다 야쿠힌 고교 가부시키가이샤 융합 환형 화합물
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
MX2009003972A (es) 2006-10-19 2009-04-27 Takeda Pharmaceutical Compuesto de indol.
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
EP2118066A1 (en) 2007-02-09 2009-11-18 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
JP2011502958A (ja) 2007-06-19 2011-01-27 武田薬品工業株式会社 グルコキナーゼ活性化インダゾール化合物
HUE028064T2 (en) 2007-12-03 2016-11-28 Obe Therapy Biotechnology Inhibitors of enteropeptidase boropeptide and their use in the treatment of diseases associated with obesity, overweight and / or abnormal fat metabolism
PL2511271T3 (pl) 2009-12-07 2015-06-30 Ea Pharma Co Ltd Pochodna estru kwasu heteroarylokarboksylowego
EP2725016B1 (en) 2011-06-07 2016-12-21 EA Pharma Co., Ltd. Heterocyclic carboxylic acid ester derivative
EP2757093B1 (en) 2011-09-15 2016-12-07 Astellas Pharma Inc. Guanidinobenzoic acid compound
EP2800579B1 (en) 2012-01-03 2017-08-30 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
EP2964644B1 (en) 2013-03-08 2018-12-26 Amgen, Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
RS57568B1 (sr) 2013-03-13 2018-10-31 Takeda Pharmaceuticals Co Jedinjenje estar guanidinobenzojeve kiseline
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
LT3046584T (lt) 2013-09-16 2017-10-10 Astrazeneca Ab Terapinės polimerinės nanodalelės ir jų gamybos būdai ir panaudojimas
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP6602778B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
ES2750956T3 (es) 2014-02-13 2020-03-30 Incyte Corp Ciclopropilaminas como inhibidores de LSD1

Also Published As

Publication number Publication date
MX2016010561A (es) 2016-11-16
WO2015122188A1 (en) 2015-08-20
MA39247B1 (fr) 2018-04-30
MA39247A1 (fr) 2017-11-30
TW201609677A (zh) 2016-03-16
US20150225354A1 (en) 2015-08-13
CR20160368A (es) 2016-12-01
EP3105228B1 (en) 2018-09-26
JP2017505823A (ja) 2017-02-23
EA201691624A1 (ru) 2017-05-31
ECSP16067163A (es) 2017-10-31
CA2939675A1 (en) 2015-08-20
AU2015216439A1 (en) 2016-08-11
KR20160113299A (ko) 2016-09-28
IL247018A0 (en) 2016-09-29
BR112016018548A2 (pt) 2019-01-15
US10023544B2 (en) 2018-07-17
JP6458054B2 (ja) 2019-01-23
EP3105228A1 (en) 2016-12-21
SG11201606176YA (en) 2016-08-30
US20160347724A1 (en) 2016-12-01
UY35995A (es) 2015-08-31
PH12016501614A1 (en) 2017-02-06
US9428470B2 (en) 2016-08-30
PE20161396A1 (es) 2017-01-10
CN106170487A (zh) 2016-11-30
CL2016002023A1 (es) 2017-03-24

Similar Documents

Publication Publication Date Title
AR099399A1 (es) Compuesto heterocíclico
NI202000092A (es) Compuestos
ECSP16067137A (es) Compuesto heterocíclico fusionado
CL2017000705A1 (es) Nuevos compuestos
MX2017006224A (es) Derivados heterociclicos y usos de los mismos.
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CY1120454T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
CY1123842T1 (el) Ετεροαρυλικες ενωσεις για τη θεραπευτικη αντιμετωπιση οφθαλμικων νοσων
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
AR103680A1 (es) Inhibidores selectivos de bace1
BR112018075736A2 (pt) composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
AR097932A1 (es) Antagonista del receptor de somatostatina del subtipo 5 (sstr5)
AR128158A2 (es) Compuesto heterocíclico
PE20170137A1 (es) Nuevos compuestos
AR103354A1 (es) INHIBIDORES DE 3-FLUORO-BENZONITRILO DE 11-b-HIDROXILASA
EA201792670A1 (ru) Производные 2-(1-гетероарилпиперазин-4-ил)метил-1,4- бензодиоксана в качестве альфа2c-антагонистов
MX2020008066A (es) Formas de sal de compuesto organico.
UY34194A (es) ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
DOP2017000016A (es) Nueva sal de disoproxilo de tenofovir
AR110226A1 (es) Inhibidores selectivos de hdac1,2
AR115865A2 (es) Compuestos terapéuticos
JP1632254S (ja) 注射器用ラベル
UA97377U (en) 3 - ((2-chloroethyl) thio) -5- (3,4,5-trimethoxyphenyl) -1h-1,2,4-triazole which exhibits hypoglycemic activity

Legal Events

Date Code Title Description
FB Suspension of granting procedure